title: A randomized, controlled trial of nebulized 5% hypertonic saline and mixed 5% hypertonic saline with epinephrine in bronchiolitis.
abstract: BACKGROUND
  Bronchiolitis is a public health problem in the word and in Tunisia. Nebulized hypertonic saline seems to have some benefits in bronchiolitis. The aim of this study is to evaluate the efficacy of nebulized 5% hypertonic saline alone or mixed with epinephrine in bronchiolitis as measured by improvement in clinical score, oxygen saturation or reduction in duration of hospitalization.
  
  
  METHODS
  This prospective, double blind, placebo controlled, randomized clinical trial was performed at Children's Hospital of Tunis from February 2012 to Mars 2012. A total of 94 patients less than 12 months of age with diagnosis of moderately severe bronchiolitis were enrolled and assigned to receive 5% nebulized hypertonic saline, mixed 5% hypertonic saline with standard epinephrine 0,1% or normal saline (placebo) at admission and every 4 hours during hospitalization.
  
  
  RESULTS
  There were no significant difference between nebulized 5% hypertonic saline, mixed 5% hypertonic saline with epinephrine or normal saline at baseline, T30 min, T60 min, and T120 min after start study in Wang severity score, oxygen saturation in room air, rate respiratory and heart rate. There was no difference in duration of hospitalization.
  
  
  CONCLUSIONS
  Nebulized 5% hypertonic saline or mixed 5% hypertonic saline with epinephrine are safety but does not appear effective in treating moderately ill infants with the first acute bronchiolitis.
authors: Faten
authors: F
authors: Tinsa
authors: Sana
authors: S
authors: Abdelkafi
authors: Imen
authors: I
authors: Bel Haj
authors: Samia
authors: S
authors: Hamouda
authors: Ines
authors: I
authors: Brini
authors: Bechir
authors: B
authors: Zouari
authors: Khadija
authors: K
authors: Boussetta
mesh_terms: D000280:Administration, Inhalation; D001988:Bronchiolitis / Q000188:drug therapy* / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009330:Nebulizers and Vaporizers; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage* / Q000009:adverse effects; D014416:Tunisia / Q000453:epidemiology
chemical_list: D012462:Saline Solution, Hypertonic; D004837:Epinephrine